Unknown

Dataset Information

0

Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.


ABSTRACT: OBJECTIVE:To assess the safety and efficacy of 2 repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS). METHODS:In a phase 2 randomized controlled trial (NCT01363401), 64 participants with ALS were randomly assigned treatments (1:1) of riluzole alone (control group, n = 31) or combined with 2 BM-MSC injections (MSC group, n = 33). Safety was assessed based on the occurrence of adverse events. The primary efficacy outcome was changes in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score from baseline to 4 and 6 months postinjection. Post hoc analysis includes investigation of cerebrospinal fluid biomarkers and long-term survival analysis. RESULTS:Safety rating showed no groupwise difference with absence of serious treatment-related adverse events. Mean changes in ALSFRS-R scores from baseline to 4 and 6 months postinjection were reduced in the MSC group compared with the control group (4 months: 2.98, 95% confidence interval [CI] = 1.48-4.47, p < 0.001; 6 months: 3.38, 95% CI = 1.23-5.54, p = 0.003). The MSC group showed decreased proinflammatory and increased anti-inflammatory cytokines. In good responders, transforming growth factor ?1 significantly showed inverse correlation with monocyte chemoattractant protein-1. There was no significant difference in long-term survival between groups. INTERPRETATION:Repeated intrathecal injections of BM-MSCs demonstrated a possible clinical benefit lasting at least 6 months, with safety, in ALS patients. A plausible action mechanism is that BM-MSCs mediate switching from pro- to anti-inflammatory conditions. A future randomized, double-blind, large-scale phase 3 clinical trial with additional BM-MSC treatments is required to evaluate long-term efficacy and safety. Ann Neurol 2018;84:361-373.

SUBMITTER: Oh KW 

PROVIDER: S-EPMC6175096 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.

Oh Ki-Wook KW   Noh Min-Young MY   Kwon Min-Soo MS   Kim Hyun Young HY   Oh Seong-Il SI   Park Jinseok J   Kim Hee-Jin HJ   Ki Chang-Seok CS   Kim Seung Hyun SH  

Annals of neurology 20180831 3


<h4>Objective</h4>To assess the safety and efficacy of 2 repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS).<h4>Methods</h4>In a phase 2 randomized controlled trial (NCT01363401), 64 participants with ALS were randomly assigned treatments (1:1) of riluzole alone (control group, n = 31) or combined with 2 BM-MSC injections (MSC group, n = 33). Safety was assessed based on the occurrence of adverse events. The p  ...[more]

Similar Datasets

| S-EPMC4035799 | biostudies-literature
| S-EPMC6431432 | biostudies-literature
| S-EPMC7456414 | biostudies-literature
| S-EPMC8363480 | biostudies-literature
2012-07-25 | E-GEOD-39644 | biostudies-arrayexpress
2003-11-14 | GSE833 | GEO
2012-07-26 | GSE39644 | GEO